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abstract 
 
The present internship report is a detailed description of my experience in 
the curricular internship performed at the Clinical Pharmacology Unit of the 
Instituto de Medicina Molecular, from October 13th 2014 to June 5th 2015. This 
internship was performed as part of the second and final year of the Master’s 
Degree in Pharmaceutical Biomedicine of the University of Aveiro. 
During the course of the experience I had the opportunity to participate in 
several projects in collaboration with different teams, most relevantly the 
activities related to the regulatory submission of a clinical trial in Portugal and 
related to the training in Pharmacovigilance. 
This internship has allowed me to put into practice the knowledge acquired 
during my academic training and deepen my knowledge on Clinical Research in 
a practical perspective. Additionally, it has also allowed me to improve many of 
skills and to understand my interests, capacities, weaknesses and strengths. 
In conclusion, I can affirm that this internship was an outstanding training 
and a very valuable professional and personal experience, for the main 
established objectives were achieved and exceeded.  
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1. Introduction 
The present document is a report about my curricular internship as part of the second year 
of the Master’s Degree in Pharmaceutical Biomedicine of the University of Aveiro. This internship 
was performed in the Clinical Pharmacology Unit (CPU) of the Instituto de Medicina Molecular 
(IMM), from October 13th 2014 to June 5th 2015. 
The aim of this internship was to consolidate and improve the knowledge about Clinical 
Research, including Clinical Trials, Pharmacovigilance and Medical Writing, and to acquire new 
skills in a real work environment. 
The learning outcomes for this on-the-job experience on the CPU were defined in the 
beginning of the internship and have been being improved in order to meet the new challenges and 
activities proposed during its course. Hereupon, the final learning outcomes defined for this 
internship are described below: 
• Improve the knowledge and skills in Pharmacovigilance and acquire qualifications to 
perform the daily activities of a regional unit integrated in the Pharmacovigilance 
National System;  
• Acquire knowledge about all the procedures and steps to obtain the legal approvals and 
ethic opinions for a clinical trial; 
• Acquire basic knowledge about the functioning of the central statistical monitoring 
approach in clinical trials; 
• Acquire knowledge and skills in Medical Writing and about the process for publication of 
scientific articles; 
• Develop personal, interpersonal and professional skills in an interdisciplinary 
environment, such as communication, organisation, critical thinking, problem solving, 
autonomy, and responsibility; 
• Write a scientific paper related to Clinical Research. 
The accomplishment of a high level of these learning outcomes at the end of the internship 
will certainly provide me a very comprehensive training in the mentioned areas as well as a 
personal and professional growth. 
This report is organised in chapters and subchapters, starting with institutional, scientific 
and academic background, followed by the internship activities and finalising with the discussion 
and the conclusion.  
In the second chapter it is provided an overview of the host institution, which complement 
this introductory information. 
In order to frame the activities carried out, the third chapter is a review about the current 
knowledge of the main areas that were developed during this period. Hereupon, the three main 
 2 
sections are as follow: Clinical Research - with its conception, evolution, the development of a 
clinical trial, and clinical data management as its main points; Pharmacovigilance – with a brief 
mention on its historical perspective, its regulatory environment and regulatory entities in the 
European Union (EU), the Pharmacovigilance National System (NPS), and the European 
legislation for Pharmacovigilance; and Medical Writing - which describes the general process, 
from manuscript writing to scientific article publishing. 
Therefore, on the fourth chapter, the activities developed are described in detail, and 
distributed by each department I worked at.  
Also, the main obstacles faced during this period, altogether with the experience, skills 
acquired, and learning outcomes achieved are profoundly reviewed in the discussion section, taking 
into account the initial objectives. 
Finally, the report ends with a global conclusion of the internship, with a special emphasis 
on the professional and personal goals achieved.  
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2. Vision of the Host Institution 
As previously mentioned, the curricular internship was performed in the CPU of the IMM 
and in order to provide the reader an overview about the host institution, in the following 
paragraphs, it will be provided a brief description about its work units and their main objectives.   
 
2.1. Instituto de Medicina Molecular 
The IMM is an Associated Laboratory of the National Ministry of Education and Science 
which is mainly supported by national and EU funds, as well as by peer reviewed competitive 
grants, private donations and industrial partnerships (1). It was created in 2002, as the result of the 
association of five research units from the Faculty of Medicine of the University of Lisbon (FMUL 
- Faculdade de Medicina da Universidade de Lisboa): the Biology and Molecular Pathology 
Centre, the Lisbon Neurosciences Centre, the Microcirculation and Vascular Pathobiology Centre, 
the Gastroenterology Centre and the Nutrition and Metabolism Centre (1). 
This private and non-profit association is located on the campus of the FMUL, in Lisbon, 
being its main mission: the development of basic, clinical and translational biomedical research 
with the aim to contribute to a better understanding of disease mechanisms, developing novel 
predictive tests, improving diagnostics tools and developing new therapeutic approaches; the 
support of scientific postgraduate training of young graduates, doctors and other health 
professionals; and the support of science communication and the provision of external services in 
the areas of specialised diagnosis, health expertise, quality control and collaboration in national and 
international committees (1, 2). 
 
2.2. Clinical Pharmacology Unit (Joaquim Ferreira Lab) 
The CPU, also known as Joaquim Ferreira Lab, is part of the IMM’s research laboratories 
and was formally created on the 1st of July of 2013, based on the research team from the 
Neuropharmacology Unit of the Neurological Clinical Research Unit and the members of the 
FMUL’s Laboratory of Clinical Pharmacology (3). This internship was conducted under the 
supervision of Professor Joaquim Ferreira, director of CPU. 
The unit is physically located in the Laboratory of Clinical Pharmacology and Therapeutics 
(LFCP - Laboratório de Farmacologia Clínica e Terapêutica) on the third floor of the Santa Maria 
Hospital, in Lisbon. Currently, the LCPT is responsible for the “Clinical Pharmacology and 
Therapeutics” curricular unit of the Integrated Master’s Degree in Medicine of FMUL; the 
collaborators of the sub-units of the CPU cooperate in teaching this curricular unit. 
The main mission of the CPU is to contribute to the development of effective and safe 
therapeutic interventions through the creation of optimised methodologies for the design, 
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conduction, analysis and report of clinical trials. The main areas of interest include the clinical 
trials methodology, outcomes, systematic reviews, and the safety and use of medicines (3).  
The main work units of the CPU are described in next paragraphs, according with the 
internal documentation of the sub-units and the information provided by the current collaborators. 
 
2.2.1. Clinical Trials Sub-Unit  
The Clinical Trials Sub-Unit is located on the sixth floor of the Neurology Department of 
the Santa Maria Hospital. This sub-unit was created in 1999 and only recently became part of the 
CPU. Its activity includes the conducting of clinical trials and observational studies of medicines, 
mainly for neurological disorders, with more than a hundred of studies performed since its creation. 
Neurological conditions such as Parkinson’s disease, Alzheimer’s disease, cervical dystonia, 
Huntington’s disease, multiple sclerosis, familial amyloid polyneuropathy, epilepsy, and psychosis 
are currently under research in this unit. 
 
2.2.2. Safety and Drug Utilisation Research Sub-Unit  
This sub-unit is part of the CPU since 2013, and it is one of the regional units of the NPS, 
also known as Lisbon and Tagus Valley Regional Pharmacovigilance Unit (UFLVT – Unidade de 
Farmacovigilância de Lisboa e Vale do Tejo), created in 2003 after the decentralisation of the 
Pharmacovigilance system in 1999.  
The National Authority of Medicines and Health Products (INFARMED – Autoridade 
Nacional do Medicamento e Produtos de Saúde, I. P.) has contracted this unit in order to perform 
actions related to Pharmacovigilance in connection with the NPS. The UFLVT actions cover more 
than 3,6 million inhabitants. Its main activities include: to receive, classify, process, and validate, 
attribute causality of the spontaneous notifications; to promote Pharmacovigilance actions and 
organise related training; to propose pharmacoepidemiologic studies, surveys, and scientific 
publications; to collaborate with the INFARMED in the NPS; and to promote the safe and rational 
utilisation of medicines. 
In what contractual purposes are concerned, the UFLVT is represented by the Association 
for Research and Development of the Faculty of Medicine (AIDFM - Associação para a 
Investigação e Desenvolvimento da Faculdade de Medicina), created in 1993 with the development 
and support of training/formation organised by the FMUL being its main purpose, as well as to 
promote and support research activities and disclose its results, among others. 
In regards to the human resources of the UFLVT, it includes one physician and two 
pharmacists with training experience in Pharmacovigilance, and an administrative assistant. One of 
the pharmacists accumulates the function of quality manager.   
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2.2.3. Biostatistics and Methodological Sub-Unit  
After the creation of the CPU, the Biostatistics and Methodological Sub-Unit was 
established in order to support the activities developed by the unit itself. This sub-unit has its main 
focus on statistics, Clinical Data Management (CDM), Medical Writing, project management, and 
other support activities. This sub-unit provides statistical support to all research projects, mainly 
related with design and analysis of clinical trials and systematic reviews and methodological 
support to the design, conduct, analysis and reporting of clinical research studies and to optimize 
study design and feasibility. 
 
2.2.4. Drug Evaluation and Systematic Reviews Sub-Unit 
This sub-unit integrates the Movement Disorders Cochrane Collaboration Review Group. 
The review group is affiliated to the Cochrane Collaboration, which is an independent, non-profit 
and non-governmental organisation, operating in more than 120 countries (4). Its mission is to 
assure the accurate assortment of medical research information in a systematic review approach in 
order to support the decisions of health professionals, patients and authorities related to health 
interventions by the Evidence-Based Medicine (EBM) principles (4). 
The tasks that are performed in this sub-unit allow the development of databases with 
updated, concise, reviewed and accessible medical research information. 
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3. Aspects of Medicines Development and Safety 
The aim of this chapter is to provide the reader a background about the three main areas 
involved in the on-the-job training: Clinical Trials, Pharmacovigilance and Medical Writing. 
The first area presented is the Clinical Trials, starting with a brief introduction about the 
subject, including its evolution throughout the years. Also, the main procedures to create, authorise 
and conduct a clinical trial, and to manage clinical data will be mentioned. The last subsection 
includes the current state of clinical trials in Portugal. 
The Pharmacovigilance section includes a historic review since the early ages to the 
present day, the regulatory entities and organisations in the EU, the current European and 
Portuguese legislation, the used tools in the Pharmacovigilance activities, and a detailed 
perspective of the Pharmacovigilance system in Portugal.  
The last subject is the Medical Writing, where the general concepts and the process from 
the manuscript writing to the scientific document publication or release are described. 
 
3.1. Considerations about Clinical Trials 
The definition of Clinical Research was never a black and white expression. As a matter of 
fact, a wide range of definitions were written and published throughout the years - some authors 
have defended Clinical Research as a set of studies with intervention in humans only; others 
include any research design that includes human studies or any samples taken from them, and 
others also include animal studies if the results will be directly applied to humans (5). Some of 
these definitions may be more valid than others, however, the Patient Oriented Research can be 
considered as a consensual expression in what concerns the explanation of the term Clinical 
Research, as it regards the aetiology, prevention, diagnosis or treatment of human diseases 
conducted in human subjects/populations, either with biological material or information of human 
origin, having a direct interaction between the subject and the investigator, and that can be 
considered the most embracing yet specific way to describe it (5). 
Clinical Research can be divided in two major categories of studies: the clinical trials (or 
interventional studies) and the observational studies, its main differences are at the level of medical 
intervention done on the participants. In fact, clinical trials intends to do an in-depth study of a 
specific intervention, for instance, a certain medicine, a medical device or a medical procedure, in 
order to determine its efficacy and safety (6). When doing observational studies researchers do not 
have any influence on the progress of events, as they only collect the relevant clinical data. 
Observational studies may be prospective (data collected forward in time) as well as retrospective 
(data collected in past events from existing source documents) (6). This report will have the 
interventional studies as its main focus.  
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The process of developing a new medicine is an extremely slow journey that can take 
between 10 to 13 years (7). In a primary process, tens of thousands of molecules with a potential 
interest are identified and studied in laboratory, with one of these molecules being selected to pre-
clinical tests (in vivo and/or in vitro) to identify its main chemical, biological and toxicological 
properties (7). If that molecule is classified as positive in the previous phase, then it is approved to 
be included in a clinical trial program. Hereupon, if the molecule is proven to be safe and effective 
during the clinical trials, it is then possible to be applied for a marketing authorisation (MA) from 
the regulatory authorities (7). 
The need to perform well-designed clinical trials comes from medicine’s demand to 
understand the very basis of diseases in order to optimise diagnostic and therapeutics, using the 
EBM approach, which is essentially a method used as a starting point for medical decisions in 
research clinical data outcomes, including randomised controlled trials, meta-analyses, systematic 
reviews, case-control studies, and all types of empirical knowledge which can support clinical 
practice. 
In the following paragraphs it is provided a vision of all the steps involved in a clinical 
trial. 
 
3.1.1. Clinical Research Evolution 
There are some milestones in history of Clinical Research that have contributed to the way 
we conduct clinical trials nowadays.  
The first ever recorded results from a clinical trial date from 250 BC, done by Galen of 
Pergamon, Greek physician, who observed differences between subjects (recovering or deceased) 
giving them the same substance in order to see the different outcomes (5). In the 1700s Scottish 
physician James Lind performed and reported the first ever considered placebo-controlled study 
with the aim of treating and preventing scurvy (5). Finally, in 1931 American physician James 
Amberson and his team, introduced the “blindness” concept in their trial with tuberculosis patients, 
with the randomisation being performed by flipping a coin to determine which group will receive 
the medicine (5, 8). Fisher has then introduced the concept of randomisation in the first edition of 
his book The Design of Experiments (1935) (5, 9).  
In the following years many changes were made regarding the conduct of clinical trials: 
specific committees were created, ethic documents and guidelines were developed such as the 
Nuremberg Code (1947) – consequence of the human experiments performed in concentration 
camps during the Second World War, the Declaration of Helsinki (1964), the Belmont Report 
(1978), and the Good Clinical Practice (GCP) (1996) (5). The year of 1948 is considered to be the 
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beginning of the Clinical Research modern era, where the concepts mentioned in the previous 
paragraphs were officially validated and made way to reduce bias in the clinical results (5).  
Many clinical disasters that have happened with commercialised medicines have proved 
the professionals the utmost importance of a properly designed study and the necessity of taking a 
high control on medicines before a new marketing approval (5). These questions will be further 
discussed in detail in the Pharmacovigilance section. 
The 1970s and 1980s were very positive years in what the growth of Clinical Research is 
concerned. However, in the 1990s there was a drastic decline in the number of clinical 
investigators, forcing the authorities and the government to create granting mechanisms to support 
professionals in their careers, at the same time they had to create proper training and offer better 
facilities and equipment to investigation (5).  
Currently, the costs of research are steadily increasing, with the economic support on a 
contrary proportion, making the cooperation between industry, academia, government, non-profit 
organisations, clinical investigators, patients, payers, physicians, and regulators to be a crucial 
factor in conducting a clinical trial nowadays (10). Given the facts, these stakeholders must offer 
different resources to support the research, as money, personnel, supplies, medical equipment, 
computer support systems, and everything needed to complete the project infrastructure (10), 
however these resources are not useful without a clear plan to conduct the study. 
 
3.1.2. Creating a Clinical Trial 
After a brief historical review about Clinical Research made in the previous section it is 
easy to conclude that the tasks and steps to create a clinical trial are currently somehow more 
complex and time consuming than they were 25 years ago. 
The new Portuguese law regarding the Clinical Research (Law nr. 21/2014, of 16 of April) 
(11) defines a clinical trial as any systematic study conducted in humans or with individual clinical 
data, in order to investigate or verify the distribution or the effect of health factors, health states or 
results, health or disease processes, performance and/or safety of interventions or health services, 
through biologic, behavioural, social or organisational aspects (11). This law covers all Clinical 
Research with humans related with medicines, medical devices, cosmetics, food supplements and 
all the observational studies in Portugal. 
There are several elements to be taken into account in order to develop the ideal clinical 
trial infrastructure, with the following key elements being common to all clinical trials: Investigator 
recruitment; a team with experience in clinical trials; protocol development support; regulatory 
approval to conduct the study; GCP requirements - which include the informed consent, a review 
by an Ethic Committee, protection of the participants’ integrity, privacy considerations, training 
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and qualifications of the investigator, reports of adverse events (AEs); contractual agreements 
between sponsors, institutions and investigators; a plan of the participant recruitment; proper 
coordination of all centres and teams of the clinical trial; quality-control systems; data collection, 
management, and analysis; data standardisation documents; publishing of results; and the 
registration of clinical trials and results on clinicaltrials.gov (12). 
A clinical trial process has four phases that can start with a new potential medicine (which 
has to be performed during all of the phases before obtaining the MA) or with an already 
commercialised medicine that might need more in-depth study (for instance, in order to prove 
safety and efficacy to a new therapeutic indication).  
Hereupon, the four stages of a clinical trial are as follow:  
• Phase I (Human Pharmacology Trials) – also known as the first-in-man studies, is the 
phase where a few healthy volunteers or ones in a sick condition and without a 
therapeutic option are included with the aim of assessing the safety, tolerability, and the 
pharmacokinetic and pharmacodynamics profile of a new medicine (6, 13);  
• Phase II (Therapeutic Exploratory Trials) – aims to assess the therapeutic efficacy and 
safety of the medicine in patients affected by the disease that is currently in study, in 
order to select the therapeutic regimen present in the next step, with the selection of 
participants being done following very strict criteria (6, 13, 14);  
• Phase III (Therapeutic Confirmatory Trials) – covers comparative studies in big 
populations in order to demonstrate the safety, efficacy and therapeutic benefit of a 
medicine compared to a standard medicine and/or placebo (6, 13, 14);  
• Phase IV (Therapeutic Use Study) – includes the studies performed after obtaining the 
MA which are intricately related with the therapeutic indication approved, and are 
important to optimise the medicine utilisation and thus increase the knowledge about the 
medicine (for example, additional medicine or food interactions, dose-response 
assessment, and unknown AEs) (6, 13, 14). 
In the following paragraphs the process to create a clinical trial will be briefly described 
and divided in the main critical steps. 
The processes to create a clinical trial from the start begin with properly nominated 
research question, which can be formulated either after analysing a research paper, during a 
medical consultation, in a clinical procedure, during a discussion with other professionals or a 
seminar (5). All collected evidence is used to formulate the research question posteriorly redefined 
into a research hypothesis, after some literature review about the subject (5, 15).  
The next step covers the elaboration of the clinical trial protocol, which must include and 
clarify the following aspects: the general information, the background information and 
 11 
significance, the objectives and its purpose, the study design, the inclusion and exclusion criteria, 
the characteristics of the treatment, the assessment of safety and efficacy, the adverse event 
reporting plan, statistical methods, data access, quality control and assurance, ethical 
considerations, data handling and record keeping, financing and insurance, plans for publication 
and presentation, conflicts of interest, the timeline, and finally the informed consent (16). 
The trial design should be made according to the aims and methodologies defined. The 
main topics that need to be taken into account in order to properly design a clinical trial are as 
follow: population, inclusion and exclusion criteria, sites where the study will be performed, 
control(s) for the study, the endpoints, the type of blinding, and the randomisation method. 
The patient population must meet the predefined inclusion criteria, to ensure a 
homogeneous population (as much as possible) and the study can be performed in one centre 
(unicentric study) or in multiple centres (multicentric study) or even in multiple countries 
(multricentric multinational study) (7, 13).  
To have a better control over a study, the investigated medicine can be compared with 
other active medicine and/or with placebo, creating a controlled trial (7). The measures, outcomes 
and endpoints can be properly defined after some literature research about the subject that is in 
investigation, which can lead to a step back in the process in order to refine the hypothesis (15).  
A “blind” study decreases the risk of bias in the results by omitting the information about 
the medicine that the patient is receiving. Moreover, it is considered single-blinding if the patient 
does not know the information and double-blinding if both, patient and investigator are unaware of 
the treatment (13). In an open-label study all those involved are aware about the administered 
treatment. The randomisation has several advantages in clinical trials, including the elimination of 
bias of selection and allocation of participants, the facilitation of blinding, and the maximisation of 
statistical power (17).  
After completing the protocol with all the required information it is then possible to submit 
an application to obtain the EudraCT (the European clinical trials database) number and to apply 
for the clinical trial approval by the authorities. 
 
3.1.3. Getting the Legal and Ethic Approvals for a Clinical Trial 
To perform a clinical trial in Portugal it is necessary to obtain an authorisation from the 
INFARMED, an ethical opinion from the National Ethics Committee for Clinical Research (CEIC 
– Comissão de Ética para a Investigação Clínica) and an approval from the National Data 
Protection Authority (CNPD – Comissão Nacional de Proteção de Dados). All applications can be 
submitted in parallel or at separated times, in any order. During the process, there is no 
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communication between the INFARMED and CEIC or local ethics committees unless requested by 
one of them. 
The new Clinical Research national law (Law nr. 21/2014 of 16 of April) (11) created an 
electronic platform, named as the National Register of Clinical Trials  (RNEC – Registo Nacional 
de Estudos Clínicos), for the online submission of all the applications for clinical trials/studies. 
This new approach aims to promote the interaction between the different stakeholders in Clinical 
Research, facilitating and encouraging high quality research development for the benefit of patients 
as well as the dissemination of national Clinical Research to the general public, professionals and 
researchers (11, 18). The potential of this platform is enormous since it promises to bring together 
all the information about the current Clinical Research in Portugal in one location. However, the 
web portal is not operational yet (19), and the applications are still submitted in paper format and in 
a CD-ROM.  
In the following paragraphs it will be presented a brief description about the different 
entities, which assess the clinical trials applications. 
INFARMED is the competent authority, under the auspices of the Ministry of Health, who 
evaluates, authorises, regulates and controls the human medicines and health products (medical 
devices, homeopathic products and cosmetics) in Portugal, in order to guarantee its quality, safety 
and efficacy and ensure appropriate standards of public health and consumer protection (20). The 
competent authority has 30 days to assess the clinical trial application; this timeline can be 
extended in 20 days for medicines with biologic products or components of human or animal 
origin, medicines for gene or somatic cell therapy, and medicines containing genetically modified 
organisms (11, 21). If the authority decides to consult an expert group or committee, the timeline 
can be extended in 50 days (11). No deadline was set for the validation of amendments to the 
research protocol; nevertheless the national competent authority is invited to respond in 35 days 
(21). The validation of the submission is included in this timeline. If the application is not 
considered valid, the INFARMED should inform the applicant in the first 10 days of the timeline 
with the reasons reported (21). The clinical trial authorisation is only valid in Portugal. 
CEIC is an independent and multidisciplinary entity with the aim to ensure the protection 
of the rights, safety and well-being of participants in clinical trials and clinical studies (of 
medicines and medical devices, respectively), by issuing an ethical opinion about the research 
protocols and other related documents submitted. That task can also be delegated to a local ethics 
committee if considered appropriated by the CEIC. The parameters assessed are the following: the 
relevance and the design of the study, the benefit-risk profile of the intervention, the ability of the 
team, the human and material resources of the research centres concerned, the participants 
compensation for damages, insurance, monetary rewards, recruitment methods, procedure to obtain 
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the informed consent and autonomy of participants, and the circuit and accessibility of the 
medicine (22). The deliberation is then communicated to the applicant, to the INFARMED and to 
the local ethic committees of the sites involved in the research. All applications have a number 
assigned by CEIC (or the Eudra-CT number) that can be searched by the applicant on the CEIC 
website in order to consult the evaluation process (23). The ethical opinion is normally issued in 30 
days. The applicant can submit a substantial amendment to the protocol during the assessment 
process, and the new ethical opinion is communicated in 20 days (11). If the application is not 
considered valid, the CEIC should inform the applicant in the first 10 days of the timeline with the 
reasons reported (21). 
CNPD is also a national independent entity, which has the power to supervise and monitor 
the compliance altogether with the personal data protection laws and regulations, to guarantee the 
human rights and the fundamental freedoms stated in the Constitution and the law (24). The 
submission is made by an electronic form in the CNPD website and the decision is usually 
communicated 30 days after the submission (11).  
The recently created National Network Of Ethics Committees (RNCES - Rede Nacional de 
Comissões de Ética para a Saúde), constituted by CEIC and the local ethic committees, aims to 
enhance the communication between local committees, to promote the development and support to 
the activities of the local committees, to decrease the deliberation time and the accumulation of 
applications, to promote the mutual recognition of the ethic opinions between committees, the 
discussion about ethics in Clinical Research and clinical practice, the proper training to 
investigators and health professionals, and to facilitate the sharing of resources, information and 
good practices between committees (11, 25). 
The submission process and the required documents for each entity will be discussed 
further in more detail in the chapter 4, related to the developed activities.  
 
3.1.4. Conducting a Clinical Trial 
After getting the legal and ethics approvals, the study can start in the selected centres. The 
first step involves an initiation visit, where the sponsor delegates to a representative team the task 
to go to the centres and therefore explain the procedures to the clinical trial team, in order to 
answer or clarify any question. The clinical trial team usually includes a Principal Investigator (PI), 
a Sub-Investigator, a study nurse, a study coordinator, among other professionals, depending on the 
requirements of the study. 
The following step includes the patient recruitment, also called the pre-screening visit, 
which starts with an explanation about the trial performed by a physician of the team who receives 
a copy of the informed consent to be read carefully. The informed consent aims to inform and 
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clarify the participant about all the procedures and data collected during the study, as well about its 
own rights (16). The participants can leave the clinical trial at any stage of the research without 
having to explain their reasons.  
After analysing the information provided about the clinical trial, if the patient decides to 
participate in the study, it is necessary to schedule an appointment to sign the informed consent in 
the presence of the PI.  
The screening visit aims to evaluate if the participant fits in the inclusion and exclusion 
criteria of the research protocol. If the participant meets the defined criteria then following stage is 
the baseline of the trial.  
The treatment period starts after the performance of participants’ randomisation (if 
required in the research protocol) and the appropriate distribution of medication. During this period 
the participant will need to visit the centre for medical appointments and to collect the necessary 
clinical data, according with the timeline and the requirements defined in the research protocol.  
At the end of the study, the participants can enter in a follow-up phase, and the medicine 
can be given to them in an open-label approach until is it on the market, if stated in the research 
protocol. 
During the clinical trial process it is the sponsor’s responsibility to monitor the study in 
order to ensure the rights and well-being of participants; to verify if data are accurate, complete, 
and verifiable from source documents; and if the conduction of the trial is in compliance with the 
research protocol, with GCP, and with the regulatory requirements (16). The monitoring visits to 
the centres follow the sponsor’s Standard Operating Procedures (SOPs), and a report to the sponsor 
for each site of the clinical trial should be written by the monitor at the end of the visit (16). 
Since Clinical Research is a highly regulated area, all these activities described above 
follow important international policies, directives and recommendations, such as the Declaration of 
Helsinki, the GCP of the International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH), Directive 2001/20/CE, Directive 
2005/28/CE, and Directive 95/46/CE. A brief review about each document will be made in the 
following paragraphs. 
The Declaration of Helsinki (26) was developed by the World Medical Association 
(WMA) and officially adopted in 1964. The current version is the seventh revision of the 
document, and was revised in the 64th WMA General Assembly, in October of 2013 (26). The 
document is considered the cornerstone for Clinical Research, since it states the ethical principles 
to guide the research involving humans, in order to put the well-being of the study participants 
before science and society (27). These principles are primarily addressed to physicians however, 
the WMA advises all the professionals involved in Clinical Research to adopt them (26).  
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The GCP document was created by ICH in 1996, in order to internationally standardise the 
ethical and scientific quality requirements for designing, conducting, recording, and reporting 
clinical trials involving human subjects (16). The guideline also details the responsibilities of the 
ethic committee, the investigator, and the sponsor and refers the information that must be included 
in the clinical trial protocol, Investigator’s brochure and other essential documents to conduct the 
study (16). If these standards are followed then it is possible to ensure that the rights, safety and 
well-being of participants are protected and the clinical data obtained are reliable (5, 16). The ICH-
GCP guideline is valid in the EU, Japan and United States of America (USA), which facilitates the 
acceptance of the clinical data by the different regulatory authorities (16). For clinical investigation 
with medical devices in human subjects the International Organization for Standardization (ISO) 
created the ISO 14155:2011 (also referred as ISO-GCP) (28). These international standards are 
transposed into legal requirements by laws and regulations to each national authority. 
The Directive 2001/20/CE (29) currently regulates the Clinical Research in EU, defining 
the requirements for conducting clinical trials. This directive was transposed into the Portuguese 
law by the Law nr. 46/2004 of 19th of August, recently revoked by the Law nr. 21/2014 of 16th of 
April (11), already mentioned. 
The Directive 2005/28/CE (30) lays the principles and guidelines for GCP of 
investigational medicines for human use, and the requirements for the authorisation of  
manufacture and importation. This directive was transposed into the Portuguese law by the Decree-
Law nr. 102/2007 of 2nd of April (31). 
The last described legislation in this chapter is the Directive 95/46/CE (32) on the 
protection of personal data, transposed to the Portuguese law by the Law nr. 67/98 of 26th of 
October (33) and by the Deliberation nr. 333/2007 of CNPD, this last one regarding clinical trials 
with medicines for human use (34). 
 
3.1.5. Clinical Data Management 
The clinical data generated by clinical trials are the “diamond in the rough” of Clinical 
Research. The management of clinical data has the purpose to generate data of high-quality, 
reliable and statistically significant, in order to get as much information as possible from the study 
and to reduce the time of medicine development (35). 
A CDM team is involved in all the stages of a clinical trial. Some of the activities in CDM 
are the following: the design of Case Report Form (CRF) to collect the data, the database 
designing, the data-entry, the data validation, the management of inconsistencies, the medical 
coding, the data extraction, the data quality control, and the de-identification/anonymisation of data 
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(35). The data quality control and the de-identification activities will be the focus of this section, 
with a brief description on the following paragraphs. 
The data quality control procedures has the identification of data processing as its main 
purposes, data entry or coding errors; protocol deviations; missing data; early withdraws; and 
problems with the database. After the identification of these problems they shall be reported with 
feedback to the data managers, biostatisticians, and clinical trial team (36). 
To prevent the participant’s identity to be linked to clinical data is possible to apply 
specific techniques; de-identification is one of the approaches that can ensure that. Before going 
any further is necessary to understand that de-identification is different from anonymisation. The 
de-identification approach refers to a severing of a data set from the identity of the participant’s; 
however, the identifying information can be preserved and could be re-linked by a trusted entity in 
specific circumstances (37). The anonymisation approach refers to irreversibly severing a data set 
from the identity of the participant’s to prevent any potential re-identification, even by a trusted 
entity (37). 
There are several main steps to implement a de-identification system. The first step is to 
collect, clean and organise the data; the second step is to select the identifiers from the data set; and 
the third step is to calculate the identifiability level through the assessment of the replicability, 
resource availability, distinguish and risk assessment (38). The methods of de-identification can be 
divided into statistical (statistical and scientific principles and methods) or heuristic methods (rules 
to distinguish between variables to generalise and variables to exclude from the data set), in a 
simpler way, the data can be de-identified by removing most of the identifiers or the critical ones; 
coding and encryption; statistically confirming an unlikely identification; and aggregating data (39-
41). After the de-identification process being completed is necessary to assess the risk of re-
identification (39). 
The processed data obtained after all these steps and methods can result posteriorly in a 
scientific paper, for example. The importance of data sharing and the Medical Writing area will be 
discussed further in section 3.3. 
 
3.1.6. Clinical Trials in Portugal 
The current state of clinical trials in Portugal is still far from the optimal results and from 
the potential of the country. The percentage of clinical trials per million people in Portugal is 
among the lowest in Western Europe (42). 
Between 2006 and 2014 the number of clinical trials submitted for approval dropped from 
160 to 127, with 2011 being the year with less submissions (88 trials) (42). 
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Most of the performed clinical trials are sponsored by the pharmaceutical industry, and in 
2012 the economic investment reached a value of 36 million euros, resulting in a 3,5 million euros 
saving for the public expenditure in medicines and supplementary diagnosis procedures (42). In 
that year, more than 1000 jobs in the country were dedicated to clinical trials (42). The academic 
(non commercial) clinical trials are still a very small percentage (42).  
In terms of clinical development phases most of clinical trials applications submitted for 
approval are phase III studies (42).  
The main factors to the declination of clinical trials in Portugal are the weak capacity of 
patient recruitment and the complexity of legal procedures (loss of competitiveness) (43).  
However, not everything is as bad as it seems, the average time for decision by 
INFARMED has been decreasing over the years, being 33 days in 2014. Nevertheless, it is 
necessary to improve the global approval duration of clinical trials in Portugal (on average, above 
70 days) (42).  
Due to the current state of Clinical Research in Portugal, some proposals and conclusions 
have been presented in reports and analyses about the subject, such as the definition of a strategic 
outline and a political programme for clinical trials, the reassessment of the current financial 
incentives and plans for Clinical Research, the regulation review to decrease the approval time, the 
creation specialised structures to manage Clinical Research, the improvement of conditions to 
perform studies in primary care, and last but not least, the adjustment of health professionals 
careers and work schedules to the particular needs of Clinical Research (42, 43).  
 
3.2. Considerations about Pharmacovigilance 
Pharmacovigilance is an area that has been gathering enormous attention not only by the 
scientific world but also from society in general. However, the attention that is created by social 
media is not always the best, for the fact that it evokes apprehension in patients and health 
professionals, and sometimes resulting in reckless actions with more serious consequences than 
adverse reactions (44).  
The World Health Organization (WHO) defines Pharmacovigilance as “the science and 
activities relating to the detection, assessment, understanding and prevention of adverse effects or 
any other drug-related problem” (45), which aims to ensure the safety of medicines consumers. 
Currently, spontaneous reporting, intensive monitoring, and database studies can increase the 
knowledge on Adverse Drug Reactions (ADRs). Moreover, it plays an important role in Clinical 
Research, since it establishes the medicine safety profile and it is a crucial element to the 
evaluation made by the regulatory authorities. For instance, during a clinical trial the PI must report 
any significant ADRs to the appropriate parties. An adverse reaction is thus considered a Serious 
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Adverse Event (SAE) if it is related with Clinical Research, and if it results in any of the following 
outcomes: death, life-threatening experiences, inpatient hospitalisation or prolongation, any 
persistent or significant disability/incapacity, or a congenital anomaly/birth defect (46). Apart from 
these said conditions, the physician can consider it as a SAE after appropriate medical judgement, 
for instance, if any surgical intervention is required to prevent one of the mentioned outcomes (46). 
In the following paragraphs it is provided a vision about the framework of 
Pharmacovigilance in Europe and Portugal. 
 
3.2.1. Historic Review 
The safety of medicines has a long history in what concerns the human being. It is present 
in the Code of Hammurabi (a Babylonian law code - 2200 B.C.), Homer’s Odyssey, the 
Hippocratic Oath, and Galen’s writings, which already had a reference to the "first, do no harm" 
concept and showed its deep concern about the use of medicines or plants, and medical procedures 
(47, 48).  
Unfortunately, it was only after Humanity passed through horrific disasters of ADRs, that 
the discussion started to really matter and create entities and laws to supervise medicines and 
protect the human health. 
In 1906 was created the “Pure Food and Drugs Act”, which had its point on prohibiting the 
commercialisation of adulterated food and medicines to regulate the labelling of products. This law 
did not mention any requirements about safety and efficacy, however, it allowed the possibility to 
withdraw medicines in commercialisation by the Food and Drug Administration (FDA) (47, 48). 
The “Food, Drug and Cosmetic Act” was the first law to require tests to demonstrate the 
low toxicity of medicines before commercialisation. It was created in 1938 after the first big 
iatrogenic disaster caused by poisoning with diethylene glycol, used as solvent in the preparation of 
the medicine elixir sulphanilamide for streptococcal infections (48, 49). 
In the late 1950s the existing clinical safety information about most medicines was still 
very poor, and that was the reality about the information for thalidomide, primarily prescribed as 
sedative and hypnotic and, subsequently, used by pregnant women against nausea and to relieve 
morning sickness (50, 51). Thalidomide was marketed as a very safe medicine in Europe, Australia 
and Japan, based on the available clinical data. However, in the early 1960s this treatment resulted 
in more than 10,000 children with severe congenital malformations, such as phocomelia 
(malformation of limbs), amelia (absence of limbs) and also deformities in ears, eyes, heart and 
gastrointestinal system (50). The thalidomide's teratogenic action is the most well known disaster, 
due to the scale and the repercussions in the future. 
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The medicine was only withdrawn from the market after the first suspicious malformations 
being presented in a congress and heavily discussed in scientific journals and newspapers (50). The 
main obstacles to the withdrawal were the reluctance of the pharmaceutical company to accept the 
malformations as an adverse effect and the 60 different commercial names, which complicated the 
product identification in the different markets around the world (50). 
 As an obvious consequence, the use of thalidomide in pregnancy was banned in 1961, 
although it currently has the treatment of leprosy and multiple myeloma as its therapeutic 
indications (51). Also, the properties of this medicine are still under study to evaluate the 
effectiveness in other diseases (51). 
The thalidomide tragedy showed how important the safety knowledge is based on rigorous 
tests, with detailed protocols, before the marketing approval and the continuous safety monitoring, 
which is also referred as Pharmacovigilance systems (51). 
The Sixteenth World Health Assembly (WHA), in 1963, was the meeting in which the 
resolution WHA 16.36 was adopted and had the purpose to reaffirm the necessity to take actions as 
much early as possible to lead to a rapid dissemination of information about ADRs. Consequently, 
in 1968, a project was created by WHO in order to develop a international system to detect 
prematurely rare ADRs - the “International Program of Adverse Reaction Monitoring” (52). The 
WHO centre to coordinate the project was first located in the United States of America (USA), in 
collaboration with 10 other countries so the feasibility of the idea could be commonly understood 
(47, 52).  
The program was renamed to “International Drug Monitoring Programme” and moved to 
Uppsala, Sweden in 1978 (53). Currently, this program is managed the by the Uppsala Monitoring 
Centre (UMC), which is an independent organisation and an international centre for services and 
scientific research, in order to ensure patients’ safety and the effective use of medicines, in 
collaboration with 147 other countries (95% of the global population) (54). One of the main actions 
of the project was the development of a standard thesaurus to report spontaneous ADRs in a 
harmonised way (52). 
All of these efforts to enhance the safety of medicines for human use have consequently 
resulted in the withdrawal of several products over the years. However, despite the progress made 
with the development of Pharmacovigilance, ADRs are still an enormous problem in public health 
with, due to the rates of morbidity and mortality, and an enormous economic burden. 
 
3.2.2. Regulatory Entities and Organisations 
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There are several entities and organisations that have a major impact in Pharmacovigilance, 
and which will be described in the next paragraphs with a concise description about them and its 
main objectives and actions in the regulatory framework. 
Primarily we have the European Medicines Agency (EMA) - a decentralised agency of the 
EU - which aims at the protection and promotion of public and animal health, and is responsible for 
the scientific evaluation of medicines for humans and veterinary use (55). The main activities of 
EMA are as follow: MAs, the safety monitoring of medicines, referral procedures (concerns about 
the safety or benefit-risk balance), inspections, telematics systems, stimulation of innovation and 
research, and networking with other regulatory authorities and entities (56). Moreover, the EMA 
establish guidelines and give an input in legislation development. 
The Agency has seven scientific committees for medicine assessment; the following two 
are the ones that have the main impact in Pharmacovigilance. The Committee for Medicinal 
Products for Human Use (CHMP) is responsible for preparing opinions concerning the medicines 
for human use (57). The Pharmacovigilance Risk Assessment Committee (PRAC) is responsible 
for assessing and monitoring safety issues for human medicines (58). 
As mentioned before in the historic review, WHO has a major role in Pharmacovigilance 
by establishing the International Drug Monitoring Programme. This authority is responsible for 
leading global health matters, by coordinating the health systems of the member states of the 
United Nations (UN) (59). 
The already mentioned ICH is an initiative between regulatory authorities and 
pharmaceutical industry, with the aim to discuss the safety, quality and efficacy of medicines in 
order to achieve harmonisation in the interpretation and implementation of technical guidelines and 
regulatory requirements. The ICH guidelines related to Pharmacovigilance will be mentioned in 
following section. 
The Council for International Organizations of Medical Sciences (CIOMS) was created in 
1949 by the WHO and the United Nations Educational, Scientific and Cultural Organization 
(UNESCO), which create guidelines by several working groups with a big impact in 
Pharmacovigilance.   
The CIOMS working groups are: CIOMS I, International Reporting of Adverse Drug 
Reactions; CIOMS II, International Reporting of Periodic Drug-Safety Update Summaries; CIOMS 
III, Guidelines for Preparing Core Clinical-Safety Information on Drugs; CIOMS IV, Benefit-Risk 
Balance for Marketed Drugs: Evaluating Safety Signals; CIOMS V, Current Challenges in 
Pharmacovigilance: Pragmatic Approaches; CIOMS VI, Management of Safety Information from 
Clinical Trials; CIOMS VII: Development Safety Update Report (DSUR); CIOMS VIII, CIOMS 
Working Group on Signal Detection. 
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The Portuguese competent authority, INFARMED, has already been described in the 
section about Clinical Trials. In what Pharmacovigilance is concerned, the Department of Medicine 
Risk Management (DGRM - Direção de Gestão do Risco de Medicamentos) of the INFARMED is 
responsible to ensure the functioning of the NPS, more precisely, is responsible to collect, assess, 
and disclose the information about suspected ADRs (60). The NPS will be discussed further in 
detail. 
 
3.2.3. Pharmacovigilance Legislation 
The 197,000 deaths per year in the EU concerning ADRs were the basis for the 
development of Pharmacovigilance legislation. 
The aim of legislation is to reduce the number of ADRs by collecting better safety data on 
medicines, efficiently assessing safety related questions, performing effective regulatory actions, 
empowering patients, and increasing the levels of transparency and increasing communication (61). 
The current European and national legislation regulating Pharmacovigilance is: 
• The Directive 2011/62/EU of 8 June 2011 (62) amends the Directive 2001/83/EC 
(63), about the Community code relating to medicinal products for human use, as 
regards the prevention of the entry into the legal supply chain of falsified 
medicinal products.  
• The Directive 2012/26/EU of 25 October 2012 (64) amends the Directive 
2001/83/EC (63) regarding Pharmacovigilance. 
• These two directives were transposed to the Portuguese law by the Decree-Law nr. 
128/2013 of 5 of September (65), which is the 8th alteration to the Decree-Law nr. 
176/2006 (66). 
• The Regulation nr. 520/2012 of 19 June 2012 (67) about the performance of 
Pharmacovigilance activities provided in the Regulation nr. 726/2004 (68) and in 
the Directive 2001/83/EC (63). 
• The Regulation nr. 1027/2012 of 25 October 2012 (69) amending the Regulation  
nr. 726/2004 (68), regarding Pharmacovigilance. 
 
In addition to legislation, there is a guideline with procedures designed to facilitate the 
performance of Pharmacovigilance in the EU. The Good Pharmacovigilance Practices (GVPs) 
apply to EMA, to national authorities of EU and to Marketing-Authorisation Holders (MAHs), 
covering medicines authorised centrally by EMA and medicines authorised by national procedure. 
The GVP is divided in various modules covering the major processes in Pharmacovigilance: 
Module I – Pharmacovigilance systems and their quality systems; Module II – Pharmacovigilance 
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system master file; Module III – Pharmacovigilance inspections; Module IV – Pharmacovigilance 
audits; Module V – Risk management systems; Module VI – Management and reporting of adverse 
reactions to medicinal products; Module VII – Periodic safety update report; Module VIII – Post-
authorisation safety studies; Module VIII addendum I – Member States' requirements for 
transmission of information on non-interventional post-authorisation safety studies; Module IX – 
Signal management; Module X – Additional monitoring; Module XV – Safety communication; and 
Module XVI– Risk minimisation measures - Selection of tools and effectiveness indicators (70). 
There are currently some modules under development, with its release scheduled for 2015: 
Module XI – Public participation in Pharmacovigilance; Module XII – Continuous 
Pharmacovigilance, ongoing benefit-risk evaluation, regulatory action and planning of public 
communication; Module XIV – International cooperation; Module XVI Addendum I – Educational 
materials (70). 
 
3.2.4. Tools in Pharmacovigilance 
Throughout the years several tools to facilitate and standardise Pharmacovigilance 
activities were developed, with some examples of them to be concisely described in following 
paragraphs. 
The VigibaseTM database collects international medicine safety data, which can be used to 
access global data, in order to compare ADR profiles of medicines, for signal detection, to update 
Periodic Safety Update Reports (PSURs), and to perform statistical analyses (71). This database is 
developed and maintained by the UMC on behalf of the WHO. The main data sources in 
Pharmacovigilance are the Individual Case Safety Reports (ICSRs) from health professionals and 
patients; the VigibaseTM contains more than 7 million ICSRs (71).  
The WHO Drug Dictionary Enhanced and the WHO Adverse Reaction Terminology 
(WHO-ART) are dictionaries with codes to identify medicines names, to evaluate medicines 
information (72), and to code clinical information about ADRs (73), respectively. 
The ICH has also created the Medical Terminology for Drug Regulatory Authorities 
(MedDRA), a dictionary to use during regulatory processes, pre and post-marketing actions, and 
data entry, among other activities (47, 52). This one is used internationally and available in 
different languages. 
The VigiFlowTM, also developed by UCM, is a management system for ICSRs designed for 
national centres included in the “International Drug Monitoring Programme” (74). 
The Eudravigilance, launched by EMA in 2001, is an information system to manage the 
information and to report electronically Suspected Unexpected Serious Adverse Reactions 
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(SUSARs) occurring during clinical trials (75). The data is analysed at least every month and is 
published in the European database of suspected adverse drug reaction reports (75). 
In Portugal, the INFARMED created a database in 2004 to record the received adverse 
reactions, entitled as SVIG (48). This Portuguese database is connected with VigibaseTM and 
Eudravigilance. 
 
3.2.5. National Pharmacovigilance System 
In 1957, the death of some children for taking an antibiotic, was the trigger for the creation 
of a pioneer Portuguese legislation (Law nr. 41448/57) which conditioned the market authorisation 
of new medicines to a prior assessment (48).  
However, in the following years, Portugal did not follow the implementation of 
Pharmacovigilance systems by the OMS. Only after the entrance of the country in the European 
Economic Community (EEC), in 1986, the conditions were finally met for the creation of a NPS 
(48). Consequently, the Medicines Regulation (in Portuguese, Estatuto do Medicamento) was 
published in 1991 (Decree-Law nr. 72/91), where the Pharmacovigilance is mentioned for the first 
time in an official document, establishing the duty of health professionals to report the ADRs (48, 
76). 
The NPS was created in 1992 (Legislative Order nr. 107/92), with the purpose to collect 
the information from MAHs and physicians, regarding ADRs. After the creation of the 
INFARMED in 1993 (Decree-Law nr. 353/93), the implementation and divulgation of NPS was 
continued by the National Centre of Pharmacovigilance (NCP – Centro Nacional de 
Farmacovigilância) (48, 76). 
In 1999, the Ordinance nr. 605/99, defined the new objectives, functions and organisation 
for the NPS, in order to enhance the spontaneous reporting of possible ADRs. The main action was 
the decentralisation of the NPS, by the creation of the Regional Pharmacovigilance Units (RPUs) 
and the Pharmacovigilance Representatives (health professionals promoting the spontaneous 
reporting) (48). 
Those units have technical and administrative autonomy, exercising their activity in 
collaboration with the INFARMED (collaboration protocols or service agreement). The main 
activities of these units are the following: reception, classification, processing, validation, and 
causality of spontaneous report of possible ADRs; divulgation and promotion the 
Pharmacovigilance activities, and the submission proposals of pharmacoepidemiologic studies 
regarding the NPS (48). Currently, there are four RPUs, one for each region of Portugal: the 
Northern Regional Pharmacovigilance Unit, the Centre Regional Pharmacovigilance Unit, 
Southern Regional Pharmacovigilance Unit, and the, already mentioned, UFLVT (76). The 
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Autonomous Region of Azores and the Autonomous Region of Madeira report adverse reactions 
directly to INFARMED. 
In 2012, a new legislation of Pharmacovigilance was created, making several changes in 
the framework of Pharmacovigilance. The main changes were the following: the possibility of 
patients to report possible ADRs; a more comprehensive concept of adverse reaction (therapeutic 
errors, off-label use, abusive or inappropriate use, and ineffectiveness); all the ADRs must be 
reported, regardless of seriousness and expectedness; the creation of a on-line portal to the 
electronic submission of ADRs, named as Portal RAM; the MA of medicines depends on the 
submission of a risk management plan; and the health authorities being able to require post-
commercialisation studies or additional monitoring to any authorised medicine (48). 
The evolution of the NPS and the continuous efforts to enhance the performance of the 
system resulted in an increase in the number of spontaneous notifications of possible ADRs. 
During 2014, the NPS received a total of 4618 notifications, an increase of 25% compared to 2013 
and of 33% compared to 2012 (77). Of these notifications of 2014, the majority was made by the 
pharmaceutical industry (2154 notifications), the remaining were notified by physicians and 
pharmacists, and only a few were reported by nurses and users of the National Health Service (SNS 
– Serviço Nacional de Saúde) (78, 79). In 2014, the UFLVT received 881 notifications (79). 
In the first trimester of the current year (2015) the NPS received 1440 notifications, an 
increase of 31% compared with the same trimester of 2014 (80, 81). In that period of time, the 
UFLVT received 147 notifications (80). At the conclusion of this report, this was the only 
information available by INFARMED regarding the notifications received by the NPS in 2015. 
 
3.3. Overview of Medical Writing  
Medical Writing includes all the activities that involve writing scientific documents, such 
as regulatory and research-related documents; educational and promotional literature about 
medicines and diseases; journal manuscripts and abstracts; content for healthcare websites, or 
health-related magazines or news articles (82). This activity requires connection and collaboration 
between stakeholders, resources, and a great deal of effort (83). 
The level of scientific information provided in these documents depends of the target 
audience (patients, general public, physicians or regulators). Therefore, a medical writer has to 
know and understand the medical terminology and concepts, the relevant guidelines for the 
structure of specific documents, how to search in medical literature, the clinical data and how to 
present it, ethical and legal issues, the process of reviewing and editing documents, and the 
requirements to submit the document for publishing (82). All of these requirements and abilities to 
be a competent medical writer are not useful without good writing skills. 
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The writing of a scientific document starts with understanding the purpose of the document 
and goals to achieve through it, including deadlines, required data, and review process (82). The 
next step is the literature search and review of information, to support the document writing.  
After this initial phase, the writing itself starts with the first draft, usually the most time 
consuming version, since it is necessary to get familiar with the structure and the specific 
requirements of the document (82). A senior medical writer, an expert in the subject, usually makes 
the review process and the quality check of the content (82). 
The pre-final stages imply the manuscript formatting and editing (language and grammar), 
according with the requirements for publishing, if applicable (82). The final step regards the 
document publishing or release, made by an expert after the approval of the final manuscript.  
Medical Writing allows data sharing, which is encouraged in order to provide new 
knowledge to researchers, sponsors, data repositories, scientific community and general public 
(83). 
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4. Developed Activities 
The activities developed during this internship have covered several different areas, 
allowing me to also have the opportunity to work with different sub-units of the CPU and to 
communicate and work in a multidisciplinary environment. The internship started in the Safety and 
Drug Utilisation Research Sub-Unit (also known as UFLVT) with the duration of one month. 
Posteriorly, I’ve moved to an open workspace where I’ve started working with the Biostatistics and 
Methodological Sub-Unit in the CDM and Medical Writing area. Later on, I had been proposed to 
collaborate on a project with the Clinical trials Sub-Unit, which occupied most of the internship 
duration. In May, I have started the second phase of the internship in Pharmacovigilance, however I 
have continued to work in the projects related to Medical Writing and Clinical Trials. 
The schedule and duration of the activities is identified in the Gantt chart presented below. 
 
The following sections illustrate the activities that were developed, each divided by the 
units I have worked in. 
  
4.1. Safety and Drug Utilisation Research Sub-Unit 
The internship started in October in the UFLVT with two planned main phases. The first 
phase lasted for one month, and it is the one I have started my training in Pharmacovigilance in. 
First, with an introduction about the area, then through a brief oral explanation by Dr. Ana Marta 
Anes (coordinator of the ADR Spontaneous Reporting Sector in the UFLVT) as well as by reading 
some related scientific literature and guidance, as for instance, the book Farmacovigilância em 
Portugal (84), which is related to the NPS and the GVP guidelines. After the introductions were 
done, I had the opportunity to be familiarised with the Quality Management System (QMS) which 
was directed by Dr. Nádia Espada (the manager for quality in the UFLVT), who allowed me to 
 
Figure 1. Gantt chart with the schedule and duration of the internship activities 
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have access to the QMS documentation (quality manual, processes, procedures, work instructions, 
document models, and records) and explained it to me. This introduction was a good starting point 
to recall some concepts related to Pharmacovigilance and Quality Assurance and its application to 
the work reality of a regional Pharmacovigilance unit integrated in the NPS. 
After the initial training I was able to start to collaborate in the daily activities of UFLVT. 
The first task that I was assigned to was the collection of data for the elaboration of the initial 
report of a few spontaneous notifications, including the collection of the Summary of Product 
Characteristics (SPC) and the registration of the case information.  
One of the notifications that I had the opportunity to analyse was related to a severe ADR, 
a DRESS syndrome (or Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome). 
This syndrome is a severe idiosyncratic ADR with a long latency period, characterised by an 
extensive rash, fever, lymphadenopathy, hematologic abnormalities, hepatitis, and involvement of 
the kidneys, lungs, heart, or pancreas (85). Since it is a rare and severe medical condition I was 
challenged to prepare a presentation in order to inform the UFLVT collaborators and to raise 
awareness about the DRESS syndrome. To achieve this challenge I had to do an extensive literature 
research to obtain the most recent information about the medical condition in order to make a clear 
and intelligible presentation. After the oral presentation, I was congratulated for the way I 
introduced the subject, for the new information that I provided and for the discussion that was 
raised between the collaborators. 
I also had the opportunity to answer to an information request of a health professional, 
concerning the relation between an ADR and 3 different medicines. To answer the questions, I had 
once again to do a literature research about the ADR and the medicines, I had to analyse the SPCs 
to understand the possible adverse effects, the relation to the requested ADR, and the interactions 
between medicines. After collecting and analysing the information, I wrote a summary answering 
the questions and attaching the relevant original information. 
During this stage of my internship, the UFLVT was subject to a quality audit by the 
INFARMED, which aimed to assess the suitability and efficacy of the implemented QMS 
comparing with the reference standard (NP EN ISO 9001:2008) (86), the QMS documentation and 
policy, and the defined objectives. During the audit, the INFARMED identified the QMS areas 
with potential for improvement. Globally, the QMS implemented in the UFLVT meets all the 
standards required. 
The UFLVT also aims to promote the Pharmacovigilance through specific training related 
to the NPS and spontaneous notification. Therefore, in the last week of this phase of 
Pharmacovigilance training I had the chance to help in the public dissemination and preparation of 
an Intensive Course in Pharmacovigilance organised by the UFLVT, with the duration of four days. 
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The course took place in an auditorium of the FMUL during the 11th, 12th, 13th and 14th of 
November 2014. Although no longer working in the UFLVT during the course, I was still invited 
to attend. The course was lectured by the Dr. Mário Miguel Rosa (medical coordinator in the 
UFLVT and clinical pharmacology expert in the CHMP of EMA), Dr. Ana Marta Anes, among 
other health professionals. The main subjects focused and discussed during the course were the 
following: ADR mechanisms and risk factors; risk-benefit assessment; pharmacoepidemiologic 
studies; methods of medicines safety monitoring; ADR spontaneous notification; imputation and 
causality assessment systems; neuropsychiatric, cardiovascular, hematologic, dermatologic, 
paediatric, gastrointestinal, renal, and hepatic ADRs.  
In April, I was also given the opportunity to attend an oral presentation by my internship 
colleague Carla Rodrigues which was related to the MedDRA term selection (explanation about the 
dictionary in the subsection 2.2.4.), based on the recent update of the dictionary (version 18.0).  
I then returned to the UFLVT in the middle of May, for the second phase of the training in 
Pharmacovigilance. During this last phase of the internship, I was allowed to help in the main 
activities of the UFLVT.  
Some of the responsibilities of the unit, in what its daily activities are concerned, are the 
collection, management, and assessment of medicines safety data, which also include the detection 
of abnormalities in the data and to trigger safety warnings based on the evidence of ADRs. At the 
end of the day, the collaborators of the UFLVT have the task to protect and improve public health. 
When the unit receives a spontaneous notification of an ADR, it can arrive by e-mail, 
telephone, fax or mail. To be considered as valid, the report must include the following 
information: identification about the notifier (currently, any person can report an ADR); 
identification about the patient; the active substance; and a signal or symptom of an ADR. If the 
report is considered valid the case will be assessed. 
The report will be dated, signed and a number code will be assigned. In order to confirm 
the existence of the notifier and to collect additional information to write the initial report, the 
UFLVT will contact the notifier directly. 
Afterwards, the case will be added to in the SVIG and attached with a copy of the original 
report provided by the notifier. A reply is sent to the notifier with the confirmation of data 
reception and acceptance of the report. The data entry on SVIG is communicated to the 
Pharmacovigilance department of INFARMED. 
The medical coordinator of the unit must assess the notification through the analysis of the 
SPC and the PSUR of the medicine, in order to assign the proper causality category, which is 
posteriorly included in the SVIG. In accordance, with the Uppsala Monitoring Centre the causality 
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of an ADR can classified as the following: certain, probable/likely, possible, unlikely, 
conditional/unclassified, or unassessable/unclassifiable (87).  
Subsequently, a summary report about the case and all the information required will be 
written, attached to the original notification and archived in the UFLVT archive. 
Depending on the finale and gravity of the ADR, the notifier must be contacted by UFLVT 
in order to update the case until the case is considered finalised. The notifier will be then informed 
about the causality classification attributed to the notification and if any decision related to the 
medicine will be made based on the spontaneous notification.  
By the end of the internship I was able to autonomously perform some of these daily 
activities of the unit. 
 
4.2. Biostatistics and Methodological Sub-Unit 
After the first phase of the training in Pharmacovigilance had been completed, I moved to 
another room in the LFCP, an open workspace, where I started to work with the Biostatistics and 
Methodological Sub-Unit in CDM and Medical Writing.  
The sub-unit works under the central statistical monitoring approach, where data is 
checked with advanced statistical methods in order to detect research sites with abnormal data 
patterns. This approach allows professionals to reveal data issues that may remain undiscovered 
after source data verification and on-site monitoring visits, and those issues may point to other 
problems that will need corrective actions; it can highlight problems that may not be detected by 
key risk indicator methods by comparing centres on all possible variables; it is a cheaper alternative 
once the data check is made by a coordinating centre, avoiding the need to visit all sites involved 
(88). 
My first task in this unit was to make a literature research related to several methodologies 
applied in CDM. The first subject was about the methods to perform de-identification in clinical 
data, and after some research I collected the information and wrote a brief report about the different 
methodologies. A brief description about the types of de-identification was already made in the 
chapter 3. Posteriorly, I had to search for guidelines that could be applied to the release of 
databases to the general public, and I understand that there are no specific guidelines in Portugal 
for this subject and that the existing information is scarce. 
I also had the possibility to work in two projects with the statisticians of the unit, Dr. Nilza 
Gonçalves and Dr. Daisy Abreu. In one of the projects, a clinical trial about movement disorders, I 
organised data and performed data entry in a database. In the other project, also a clinical trial 
related to movement disorders, I collaborated in the creation of a report of a data cut statistical 
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analysis by filling the report with data obtained through the statistical analysis performed with the 
SPSS® software. 
 
During November I was proposed to work in several investigation projects on Medical 
Writing by the Dr. Daniel Caldeira, cardiologist intern. The majority of the projects were 
systematic reviews related to cardiology.  
In order to introduce the subject, the following paragraphs will have a brief description of 
some concepts related with systematic reviews, which I have learned during the internship. 
A review article is a critical and constructive analysis of the previously published scientific 
literature and data about a specific subject. Its function is to organise, evaluate, and synthesise the 
literature, and also to identify patterns, trends, research gaps, and recommend new research areas 
(89). The audience for a review article are experts in the subject analysed, students, beginner 
researchers, and decision-makers. 
There are several types of review articles, such as: the narrative review, which selects, 
compare and resume studies based on the author’s expertise, obtaining results at a qualitative level 
(descriptive articles); and the systematic reviews, which collects findings from multiple individual 
studies and analyses it statistically in order to obtain an high quality research evidence and an 
unbiased analysis (89, 90). 
A systematic review process requires several steps that will be described bellow.  
The first step is the definition of a proper question, through the clarification of the 
objectives of the subject under analysis, relevant population and interventions, the comparator 
group, and the types of studies and outcomes that will answer the question (90). This step includes 
the PICOS approach (participants, interventions, comparators, outcomes, and study design), which 
helps to facilitate the process by helping the formulation of pertinent and accurate questions (91). 
This step is crucial to define the studies inclusion criteria. 
The second step is the meticulous searching in the literature. To do an unbiased assessment 
is necessary to search all the literature, including non-English sources and grey literature (not 
formally published) (90). Sometimes it is also necessary to search the references of full-text papers. 
The third step involves the assessment of studies, after the identification of all possibilities 
of study. Primarily, the studies are assessed for eligibility based on the defined inclusion criteria 
and those selected will be assessed in full-text according to the following parameters: 
methodological quality, using a critical appraisal framework; and reported findings, extracted by a 
data extraction form (90). Two independent reviewers should make this evaluation. 
The following step is to combine results of the included studies. This aggregation of the 
clinical effectiveness, feasibility, appropriateness and meaningfulness related to the subject 
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assessed, is known as evidence synthesis (90). For instance, a meta-analysis can be an evidence 
synthesis, which is a statistical technique performed to estimate the net aggregated benefit of the 
studies included in that analysis. (92). The main advantages of a meta-analysis are the chance to 
obtain an unbiased, precise, and transparent synthesis of the empirical data (92).  
The systematic reviews can be published in scientific journals and databases. Taking the 
Cochrane Collaboration as an example, it electronically publishes systematic reviews, offering a 
quick access to updated articles. 
Due to the all mentioned characteristics, the systematic reviews are currently one of the 
cornerstones of EBM. 
In the Biostatistics and Methodological Sub-Unit, the ideas for the systematic reviews 
came from Dr. Daniel Caldeira’s expertise on cardiology, who has always made an explanation 
about the subject under analysis to all the collaborators involved in the project. My main duties in 
those projects were the following: selection and analysis of the articles obtained in the literature 
research, based upon the inclusion criteria; data collection; quality assessment of studies, by the 
QUADAS tool (93) (design for systematic reviews); writing of the manuscript, based in a deep 
analysis of the included studies. During this time, I’ve always had the opportunity to clarify any 
questions or concerns with Dr. Daniel, in order to improve my skills and the results from my work. 
All the drafts of the manuscript were sent to Dr. Daniel and later discussed to better develop the 
final article. In the end of the manuscript writing process, a suitable scientific journal is selected in 
order to submit the article.  
As previously mentioned, the Medical Writing projects which I was involved in were 
focused in cardiology, most of them specifically related to risk stratification tools for high bleeding 
in patients with venous thromboembolism, patient satisfaction scales with anticoagulant therapy, 
and risk of major gastrointestinal bleeding with anticoagulant therapy. 
In those projects I also collaborated with Márcio Barra who is project manager in the CPU, 
and who supported me in all the steps.  
 
In late January, my activities related to CDM had ceased. However, I continued to 
collaborate with the Dr. Daniel Caldeira and Márcio Barra in the on-going projects until the end of 
the internship, even during the second part of the Pharmacovigilance training. 
 
4.3. Clinical trials Sub-Unit 
During my time in the Biostatistics and Methodological Sub-Unit, Dr. Ana Noronha, who 
is clinical trial coordinator of the Clinical trials Sub-Unit, has challenged me to support her team in 
the submission of an academic clinical trial to the Portuguese authorities (INFARMED, CEIC and 
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CNPD). I was quite enthusiastic about the idea and the project, since I have always wanted to work 
in the area of Regulatory Affairs, and that was the perfect opportunity to apply my knowledge on 
the subject. 
However, my duties have increased over the course of this project and covered many other 
areas besides the Regulatory Affairs, such as Medical Writing and Project Management. 
The project was an extension of a French clinical trial related to the Parkinson Disease 
therapy, running in France since 2011. My first activity in this project was to update my knowledge 
on the current legislation and on the application submission process to the national authorities, by 
analysing extensively the Portuguese and European legal and regulatory framework related to 
clinical trials, and read the protocol to understand the study. After such procedure I was able to 
make a list of the required information and documents, based on the study characteristics. 
The main information and necessary documents to submit an application to the authorities 
include: cover letters; confirmation of the EudraCT number; application form; clinical research 
protocol; protocol synopsis; information about the sponsor, investigator-coordinator, and the 
principal investigators; investigator’s brochure; data about the investigational medicinal product; 
research sites identification, authorisation and facilities; insurance certificate; financial agreement; 
participants compensation; and, if available, previous authorisations of the competent authorities or 
ethics committees in other countries. 
Some of the required documents to submit a clinical trial to INFARMED and CEIC must 
be in English or Portuguese, such as the protocol and synopsis, CRF and informed consent. Since 
these documents were entirely in French, I was also challenged to do the translation of the 
documents to Portuguese. This task was really challenging to me, due to the large number of pages 
and the particular medical, pharmaceutical and statistical terms that were in French, and thus I had 
to make some research in order to do a better translation. 
A clinical trial protocol is the document that describes how the clinical trial must be 
conducted, and it aims to ensure the safety of participants and the integrity of the obtained 
outcomes and clinical data. The protocol must include the following information: project summary; 
general information; rationale and background information; study objectives; study design; 
methodology; safety considerations; follow-up; data management and statistical analysis; Quality 
Assurance; expected outcomes; dissemination of results and publication policy; duration of the 
project; anticipation of problems and limitations; project management; ethics considerations; 
informed consent forms; budget; financing and insurance; collaboration with other researchers, 
institutions or organisations; and references of the literature (94). 
A CRF is a form/questionnaire filled by the physician for each participant in the study. 
This document collects the data required and can be electronic or printed, and its design varies 
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according to the protocol. The collected data is always pre-defined in the protocol and includes 
demographic and clinical data, collected from the medical history of the patient, the information 
obtaining during the medical visits, and the procedures contemplated in the protocol. In this 
project, the CRF was in paper format.  
The informed consent is a document, with an information note attached, which must be 
signed by the participant to be part of the clinical trial. This document should include all the 
relevant information about the study, the medicine, the safety and risks of the intervention, the 
expected benefits, and the rights and duties of the participant. 
In January, I was invited to participate in a teleconference between the IMM team 
seconded for the project and the team of the sponsor, in order to be aware of the progress and 
updates related to the study. This meeting’s agenda had the following subjects: presentation of the 
Portuguese and French teams, financial support and agreements, logistical issues, and delegation of 
tasks. It was a very important meeting that focused on defining the tasks for each member of the 
two teams. 
During the translation I have also worked with the sponsor of the study in order to get all 
the necessary documentation, and to provide to the French team the required information. Some of 
those contacts with the sponsor were related with the assessment’s medical scales used in the CRF, 
which had to be translated or replaced into Portuguese or English versions, and also regarding the 
financial contract between the sponsor and the IMM. 
After the translations had been made, Dr. Ana Noronha revised the documents and some 
corrections and improvements were made. 
The following step was meant to identify and contact the research sites in order to perform 
the study, in order to assess the feasibility, identify the principal investigators and collect the 
necessary documentation. 
 I also contacted the pharmaceutical company that would provide the medicine for the 
clinical trial, to define the re-encapsulation (for blinding purposes), packaging, labelling and 
distribution of the medicine. To define that I had to calculate the necessary active medication and 
placebo throughout the study for all the patients, which are expected to be included in the study. 
Additionally, I had to create an example of the labelling for the medicine under study and for the 
placebo, and translate and adapt the template of some documents related to the supply chain 
management, such as: the e-mail to the sponsor representative about the patients’ inclusion to send 
the medicine to the research centres; the form for the medication acknowledgment of receipt for 
pharmacies of the research centres; the prescription template to release the medication to the 
patient; the form for the accounting of the returned medication; and the certificate of the medicine 
destruction. 
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Simultaneously, I have continued to collect the information for the submission of the 
application to the authorities, and I also had to complete and create relevant files, such as the cover 
letters and the application form, filled in the EudraCT website. 
 
By the time of the submission of this report, I was still working with the sponsor to submit 
the clinical trial to the Portuguese authorities.  
This project was a challenge for me, however the knowledge I acquired during my degree 
allowed me to work autonomously most of the time.  It was the most time consuming and 
hardworking activity, and required more autonomy and responsibility during the internship. 
During my collaboration with the Clinical trials Sub-Unit, I also had the opportunity to 
insert data in electronic CRFs. As mentioned, these platforms are electronic data collection tools 
provided by the sponsor of the study to the research centre. The inconsistencies, incoherencies or 
missed data are reported as data queries, which should be solved or justified by the physicians and 
the study coordinators. 
Due to the translation of the mentioned informed consent, I was later asked to verify and 
correct a translation of another informed consent, made by the sponsor of the study, that was 
refused by CEIC. 
The activities with the Clinical trials Sub-Unit lasted until the end of the internship. 
 
4.4. Other activities 
4.4.1. Training session about the Instituto de Medicina Molecular 
During my internship, as part of the host institution requirements for new collaborators, I 
had to attend a training session related to the IMM, more precisely, about the institution objectives, 
policies, hierarchy, departments, and on-going projects. The training session also included a field 
visit to the facilities of the IMM, including laboratories, scientific equipment rooms, among other 
departments, which proved to have utmost interest to my experience. 
 
4.4.2. Wednesday Afternoon Meetings 
Every other Wednesday, at 6 pm, the CPU members from all the sub-units and other 
persons who collaborate with the unit had a meeting in the LFCT with the purpose to share and 
discuss relevant topics and the on-going and future projects. In each meeting, a different 
collaborator made an oral presentation with a brief discussion with the audience in the end.  
The aim of these meetings was to update the whole team about the recent projects, new 
developments and future expectations, and the discussion provided feedback, opinions and 
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improvements to the projects leaders and participants. The multidisciplinary team of CPU was a 
major advantage, since it helped to bring new ideas and different opinions to the discussion. 
 
4.4.3. Classes about Therapeutic Research in Neurosciences 
Along with my internship colleagues, we were invited to attend some classes of the 
Master/Doctorate course in Neurosciences of FMUL. These classes included several subjects 
related to the therapeutic research in Neurosciences, such as: clinical development of medicinal 
products; clinical trial design; clinical outcomes and biomarkers; systematic reviews, meta-analysis 
and critical appraisal of data; research with non-pharmacologic therapeutic interventions; 
pharmacoeconomics; drug discovery and preclinical development; and Pharmacovigilance. 
 
4.4.4. Support activities 
I also had the opportunity to help the CPU with some support activities, such as: translation 
of documents from English to Portuguese; completing a questionnaire for a research grant call; and 
a critical analysis of an application for a research grant. 
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5. Discussion  
It is now more than recognised that Clinical Research has changed modern medicine in a 
way that the evolution of medicine throughout the last fifty years has given innumerous 
possibilities of treatments due to the improvements in the ability to effectively treat or prevent 
diseases, even in its most deadliest forms. This success has and continues to encourage the 
enthusiasm and belief in the potential of Clinical Research. 
The current high quality of medical care was built with the efforts of investigators and 
health professionals that have invested great part of their lives in Clinical Research. In practical 
terms, it all translates to clinical trials, which demonstrate to the scientific community if a 
medicine, a medical device or a medical procedure is safe and effective. Hereupon, it is easy to 
understand why Clinical Research is such an important area in medicine and why it has changed in 
so many forms the way medical practice is conducted nowadays.  
 
The internship presented in this document was performed at a clinical pharmacology unit  
involving different departments with multiple professionals from different academic backgrounds, 
a work which has allowed me to contact with different areas related to Clinical Research and 
understand how they work together with a common goal.  
This report has helped me to systematise the background information related to the areas 
that I have worked with during the internship as well as the performed activities by describing all 
the projects that I was involved in. Also, it has allowed me to understand my flaws, difficulties, 
achievements and strengths that have emerged during the internship. However, it is very difficult to 
describe properly and faithfully all the activities and outcomes of this on-the-job training in a 
report. The training, the work experience, the knowledge and skills acquired, the professional 
contacts and connections made, and the professional and personal growth have made this internship 
an extremely rich and challenging experience. 
In the following paragraphs, I will discuss some of the major difficulties and obstacles in 
carrying out some activities faced during the internship, and also the skills acquired and the 
achieved level of the learning outcomes defined at the beginning of the internship.  
The most challenging activity was the submission of an application for a clinical trial 
authorisation, which proved to be more difficult and time consuming than initially expected. Since 
the CPU did not have much experience with the submission of clinical trials, also acting as a model 
of a Contract Research Organisation (CRO), and due to its duties (described in section 4.3.) in this 
particular project, I had to research and learn the legal requirements applied to this clinical trial in 
order to understand its implications. That opportunity helped me to stimulate my critical thinking, 
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my organisation skills, my autonomy, and also my capacity to transmit the information to other 
people in the most accurate way possible.  
To overcome some difficulties and to speed up the process, I have created some personal 
tools such as: a table checklist to all the contacts made and the documents required from the 
Portuguese centres; a template of a declaration about the conditions of the research centres facilities 
to the sites without a specific template; and a table with all the required information and necessary 
documents to the clinical trial submissions for each authority. These simple tools helped me to 
organise my time, my tasks and the information collected. Also, these tools were very useful to 
communicate the process progress to the other members of the team involved in the project and at 
the same time to improve and assure the quality of my work.  
The necessity to contact multiple entities and professionals has improved my writing and 
verbal communication skills, once that I honed my dialogue during phone calls and my writing on 
e-mails making my speech more fluid, simple, assertive and more professional. Also, the 
translation of extensive documents has helped me to improve my translation skills. The opportunity 
to read and work several kinds of documentation related to clinical trials has allowed me to 
understand the complexity of the information required and the necessity to detail all the procedures 
in order to avoid any misinterpretation. 
My participation in this clinical trial project helped me immensely to acquire new skills 
and improve my personal capacities and the contact with the Clinical trials Sub-Unit has shown me 
the world of clinical trial coordination and the dynamics of a research centre.  
With this project I can affirm that I have acquired strong knowledge about the procedures 
and steps to obtain the legal approvals and ethic opinions for a clinical trial in Portugal. Moreover, 
I can also affirm that my objectives for this project were exceeded, due to all the tasks that I 
performed and the improved skills provided by an outstanding on-the-job training and important 
experience. 
By the end of the internship I could affirm that dealing with this particular part of the 
regulatory affairs of a clinical trial is not an easy task and requires a lot of concentration, 
organisation, attention to detail, capacity to deal with unforeseen situations and misunderstandings, 
ability to solve problems quickly and great communications skills. I believe that these skills are the 
pressure points of a work related to this area.  
For all those reasons and for my performance, after the initial struggles, in this task and the 
feedback that I obtained from my tutors, made this area of managing the initial steps to establish a 
project of a clinical trial one of my career interests. 
During my training in the Biostatistics and Methodological Sub-Unit I have also felt a few 
difficulties with some tasks related to statistics, once my training in this area is scarce. However, 
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the autonomous key ability acquired during my degree in Biomedical Sciences, that was taught 
according to the Problem Based Learning (PBL) method, helped me to search for information 
about the subject and learn the basics of statistics that were required to perform my tasks. 
The training in this sub-unit, working in a central statistical monitoring approach, allowed 
me to understand its dynamic and main activities. Also, I acquired knowledge about concepts that I 
was not familiarised with, such as the de-identification of data, which is a very eye-opening 
approach to use in Clinical Research, in order to prevent a person's identity from being connected 
with data itself. By the end of the internship I have acquired basic knowledge about the main 
functions of the sub-unit and the central statistical monitoring approach. The contact made with the 
Biostatistics and Methodological Sub-Unit made me more curious about this area and willing to 
learn more about it. Therefore, in the future I hope to develop the knowledge that I have acquired 
during this period of time. 
The Medical Writing related activities have allowed me to play an active role on projects, 
and to learn more about the writing of scientific articles and its submission for publication in 
scientific journals. Those activities have also helped me to improve my writing skills and my 
capacity to synthesise information. The projects developed in this area, which were related to 
cardiology and anticoagulation had a high challenging although rewarding level, due to its 
complexity, potentiality and ultimate importance for Clinical Research and daily medical practice. 
During these projects in Medical Writing I understand that more than communication and writing 
skills, it is necessary to be very interested and motivated in order to conduct the investigation and 
its objectives in an effort to publish, for instance, an article with consistent, updated and profound 
scientific information, which is imperatively required in this area. 
The fact of not having had experience in scientific writing and all the knowledge that I’ve 
acquired motivates me to explore the area of Medical Writing in the future.  
The internship began and also ended in the UFLVT. The training in Pharmacovigilance has 
allowed me to obtain knowledge and practical skills in the processing of spontaneous notifications 
of ADRs, clinical pharmacology, safety monitoring of medicines, iatrogenesis, and also in QMSs 
and its continuous improvement.  
During the time in the UFLVT it was taught me not to have shaped preconceptions. 
Meaning, the raw data is the only source of information, for the fact that if one assumes something 
based on a person’s interpretation of the data, which can lead to errors, misunderstanding, bias, and 
elimination of evidence, among other deviations to the data source. I have also improved my 
knowledge about several subjects related to the Pharmacovigilance area such as: National and 
European legal framework; European legislation; GVP; NPS and regional units activities, and 
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interactions with other health organisations or entities; the importance of medicines safety; and the 
importance of reporting spontaneously ADRs, and its limitations and difficulties.  
I have finished my internship as person that capable to autonomously perform some of the 
daily activities, such as the introduction of data in the SVIG, codification of medical terms 
according to the MedDRA dictionary, and write causality reports and letters. The time that I spent 
in the UFLVT allowed me to realise the entire process that is necessary to finalise a spontaneous 
notification. 
The possibility to read the QMS documentation (such as operational procedures, data 
records and the quality manual) allowed me to understand that it ensures that the work is 
consistent, it has the best quality possible and it is continuously improved. 
The work developed in the UFLVT showed me the importance of teamwork and necessity 
to write all the data and keep all the data sources in order to track cases, documents and 
information very quickly and avoid data gaps. Also, during the daily tasks, I understand that is 
crucial to have attention to detail when you are working with a lot of information from different 
sources that trigger different actions and result in different outcomes. 
The experience related to Pharmacovigilance obtained during this internship allowed me to 
learn much more than I expected at the beginning. And for the described experience and all the 
mentioned reasons I consider this training a great work experience and I can imagine myself 
working in this area in the future. 
At the beginning of the internship it was proposed to my colleagues and myself to write an 
individual scientific paper related to Clinical Research. However, the subject and question for the 
article never arose and this project never developed. This is the unique failure that I can point 
during the entire internship. Nevertheless, the work developed with the Dr. Daniel Caldeira has 
somehow helped overcome the failure of not achieving this goal. 
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6. Conclusion 
The present report intends to illustrate my experience in this curricular internship by 
describing the activities performed, the skills acquired and knowledge obtained during that period. 
This internship happened in an interdisciplinary environment, which allowed me to 
develop my personal, interpersonal and professional skills, such as communication, organisation, 
critical thinking, problem solving, autonomy, and responsibility. The internship at the CPU 
provided me the opportunity to contact with multiple areas related to clinical research and multiple 
professional from different academic areas working in the same projects. Moreover, it has helped 
me to know and understand my interests, capacities, weaknesses and strengths in a variety of areas, 
showing me that I appreciate to be responsible for multiple tasks in a project, involving 
communication with multiple teams. 
In global view, the internship was a success due to the skills acquired and the achieved 
level of learning outcomes. The new tasks and responsibilities, the necessity to manage your own 
work schedule and the pressure to do your best in all your activities can be stressful and scary 
sometimes. However, there is no better feeling than hear a compliment regarding your work or 
understand that somehow your work helped the team or the project to succeed. 
I can affirm that my internship was an outstanding training and a valuable professional and 
personal experience and that I am very grateful for this opportunity. The opportunity to collaborate 
in bigger projects since their beginning was the bigger challenge during the internship and the task 
that I liked most, due to the level of demand. This internship gave me more responsibilities than I 
have ever expected and helped me to improve my personal and professionals skills, and for that 
reason I am very proud of myself.  
This experience became my most important academic and work experiences so far. The 
daily routine, the amount of work and the responsibilities were very different compared to the 
routine at university. However, I had adjusted myself to this new reality and its requirements very 
quickly.  
All the acquired skills and the opportunity to improve and apply the knowledge obtained 
during my Master’s Degree has motivated me to exceed my expectations and to learn more and 
obtain the highest experience possible in this contact with the “world of labour”. 
After this challenging experience, I am eager to do and learn more and go beyond all 
possibilities given. 
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